Spero TherapeuticsSPRO
SPRO
About: Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Employees: 46
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
11% more funds holding
Funds holding: 45 [Q3] → 50 (+5) [Q4]
6.32% more ownership
Funds ownership: 22.78% [Q3] → 29.1% (+6.32%) [Q4]
1% less capital invested
Capital invested by funds: $16.5M [Q3] → $16.3M (-$165K) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
542%
upside
Avg. target
$5
542%
upside
High target
$5
542%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju 32% 1-year accuracy 109 / 342 met price target | 542%upside $5 | Buy Reiterated | 30 Jan 2025 |
Evercore ISI Group Josh Schimmer 18% 1-year accuracy 10 / 55 met price target | 542%upside $5 | In-Line Downgraded | 20 Dec 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero's Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference being held in Boston, March 3rd – 5th, 2025. Details are as follows:
Neutral
GlobeNewsWire
2 weeks ago
Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero's Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference being held in Boston, March 3rd – 5th, 2025.
Positive
Seeking Alpha
1 month ago
Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal
Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is critical due to rising resistance to current oral treatments for complicated urinary tract infections. Tebipenem's success in the confirmatory phase 3 trial is highly probable, given its prior phase 3 success and publication in NEJM.
Positive
Zacks Investment Research
1 month ago
Spero Therapeutics (SPRO) Upgraded to Buy: Here's What You Should Know
Spero Therapeutics (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
GlobeNewsWire
2 months ago
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company's Response to a Wells Notice from the SEC Relating to Certain Public Disclosures Made in 2022 Phase 3 PIVOT-PO Trial of Tebipenem HBr Reaches Over 60% Enrollment as of December 31, 2024; Remains on Track to Complete Enrollment in 2H 2025 Cash Balance and Cash Runway Guidance Remains into mid-2026 CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (“Spero” or the “Company”) (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today provided a corporate update regarding interim changes to its leadership and Board as well as an enrollment update regarding the Phase 3 PIVOT-PO trial of Tebipenem HBr.
Negative
Zacks Investment Research
2 months ago
Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Spero Therapeutics (SPRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Positive
Zacks Investment Research
3 months ago
New Strong Buy Stocks for November 15th
FHI, RJF, ASTS, APLD and SPRO have been added to the Zacks Rank #1 (Strong Buy) List on November 15, 2024.
Negative
Zacks Investment Research
3 months ago
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.02 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the third quarter ended September 30, 2024, and provided a business update.
Neutral
GlobeNewsWire
4 months ago
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
In vitro data on SPR719 show low propensity for resistance development in NTM-PD MAC strains when administered as a single agent and in combination with standard of care agents
Charts implemented using Lightweight Charts™